Afatinib Improved PFS in Lung Cancer With Uncommon Mutations

(MedPage Today) -- Patients with advanced non-small cell lung cancer and uncommon EGFR mutations lived almost twice as long without disease progression with the targeted agent afatinib (Gilotrif) versus chemotherapy, a randomized trial from Japan...